616 related articles for article (PubMed ID: 16928803)
1. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
2. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
[TBL] [Abstract][Full Text] [Related]
3. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
Chen HH; Lainchbury JG; Harty GJ; Burnett JC
Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
[TBL] [Abstract][Full Text] [Related]
4. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil.
Melenovsky V; Al-Hiti H; Kazdova L; Jabor A; Syrovatka P; Malek I; Kettner J; Kautzner J
J Am Coll Cardiol; 2009 Aug; 54(7):595-600. PubMed ID: 19660688
[TBL] [Abstract][Full Text] [Related]
5. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
Rodríguez-Iturbe B; Ferrebuz A; Vanegas V; Quiroz Y; Espinoza F; Pons H; Vaziri ND
Kidney Int; 2005 Nov; 68(5):2131-42. PubMed ID: 16221212
[TBL] [Abstract][Full Text] [Related]
6. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.
Chen HH; Cataliotti A; Schirger JA; Martin FL; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1093-7. PubMed ID: 15627648
[TBL] [Abstract][Full Text] [Related]
7. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
8. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
9. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes.
Castro LR; Verde I; Cooper DM; Fischmeister R
Circulation; 2006 May; 113(18):2221-8. PubMed ID: 16651469
[TBL] [Abstract][Full Text] [Related]
10. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Lewis GD; Semigran MJ
Curr Heart Fail Rep; 2004 Dec; 1(4):183-9. PubMed ID: 16036043
[TBL] [Abstract][Full Text] [Related]
11. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure.
Chen HH; Schirger JA; Cataliotti A; Burnett JC
Eur J Heart Fail; 2006 Nov; 8(7):681-6. PubMed ID: 16459135
[TBL] [Abstract][Full Text] [Related]
12. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
[TBL] [Abstract][Full Text] [Related]
13. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition prevents myocardial infarction-induced increase in renal cortical cGMP and cAMP phosphodiesterase activities.
Clauss F; Charloux A; Piquard F; Doutreleau S; Talha S; Zoll J; Lugnier C; Geny B
Fundam Clin Pharmacol; 2015 Aug; 29(4):352-61. PubMed ID: 25939307
[TBL] [Abstract][Full Text] [Related]
15. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
16. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction.
Lefièvre L; De Lamirande E; Gagnon C
J Androl; 2000; 21(6):929-37. PubMed ID: 11105920
[TBL] [Abstract][Full Text] [Related]
17. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
18. Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure.
Supaporn T; Sandberg SM; Borgeson DD; Heublein DM; Luchner A; Wei CM; Dousa TP; Burnett JC
Kidney Int; 1996 Nov; 50(5):1718-25. PubMed ID: 8914042
[TBL] [Abstract][Full Text] [Related]
19. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to ANP in the pregnant rat.
Knight S; Snellen H; Humphreys M; Baylis C
Am J Physiol Renal Physiol; 2007 Feb; 292(2):F655-9. PubMed ID: 17003222
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
